Risk stratification and medical therapy of pulmonary arterial hypertension

Стратификация риска и медикаментозная терапия легочной артериальной гипертензии
Nazzareno Galiè, О. М. Моисеева, Vallerie V. McLaughlin, Richard N. Channick, Tomás Pulido, Zhi‐Cheng Jing, Robert P. Frantz, Ioana R. Preston, Ekkehard Grünig, Yuichi Tamura, Zeenat Safdar
2018-12-13

combination therapylung transplantationprostacyclin pathwayspulmonary arterial hypertensionrisk stratification
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.
1
Initial treatment is selected according to risk status and may involve monotherapy or double or triple combination therapy.
2
Multiparametric risk stratification integrates clinical, exercise, right-ventricular, and haemodynamic parameters to classify patients as low, intermediate, or high risk by expected one-year mortality.
3
Pulmonary arterial hypertension remains severe despite drugs targeting the endothelin, nitric oxide, and prostacyclin pathways.
4
Recent therapeutic progress primarily reflects combination-treatment strategies and escalation guided by systematic assessment of clinical response, rather than discovery of new pathways.
5
Therapy should be escalated when follow-up assessments fail to demonstrate low-risk status; lung transplantation may be necessary for advanced disease despite maximal medical treatment.

newly diagnosed patients with pulmonary arterial hypertension (PAH)

risk stratification and treatment escalation, including combination medical therapy, based on clinical response and expected 1-year mortality

Publication Details
Publication Date
2018-12-13
Journal
Publisher
ISSN
Cited by
838
Access Type
Author Information
Authors
Nazzareno Galiè
О. М. Моисеева
Vallerie V. McLaughlin
Richard N. Channick
Tomás Pulido
Zhi‐Cheng Jing
Robert P. Frantz
Ioana R. Preston
Ekkehard Grünig
Yuichi Tamura
Zeenat Safdar
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%